Monograph
M01AC06 - Meloxicam |
Propably not porphyrinogenic |
PNP |
Rationale
Substrate for CYP 2C9 and 3A4. One list consider it probably safe.
Chemical description
Tabl, supp, 7-15 mg/d. Analgetic, antipyretic och anti-inflammatory inhibitor of prostaglandin synthesis used in osteoarthrosis. Oxicam derivative, extensively metabolized by hydroxylation by CYP 2C9 (major reaction) and 3A4 (minor reaction). Inhibitor of CYP 2C9. South African list: use with care
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland
Latvia
Serbia© NAPOS 2024